This study discovered a substantial relationship between FCGR3A and immune checkpoints, including PD-1, PD-L1, and CTLA4, suggesting FCGR3A would be a promising immunotherapy target for patients with advanced PCa. This evidence concerns the gene CTLA4 and posterior cortical atrophy.